Heidi McIntosh

USA

Heidi McIntosh, MSW, is the Chief Operating Officer at the National Association of Social Workers (NASW), renowned for designing strategic programs that enhance policies impacting organizations and vulnerable populations. With 30+ years in health and human services nationally and internationally, she focuses on racial justice, combating bias, and advancing social equity. Previously CEO of First Place for Youth, she directed national strategies for transition-age foster youth, emphasizing Race, Equity, and Inclusion. Heidi also led NASW's programs for 750,000 social workers, served as Senior Policy Advisor in the Obama Administration, and Deputy Commissioner in Connecticut. She holds degrees from UCONN in Policy and Planning, and Social Work.

A. Claudio Cuello

Canada

Dr. A. Claudio Cuello is recognized for pioneering discoveries in neuropharmacology. His most recent contributions relate to the discovery of the brain’s NGF metabolic pathway, dysregulated in Alzheimer’s disease (AD). In addition, for decades, he has promoted microlithium therapy to slow down early AD pathology, applying novel preparations to advanced rat transgenic AD models. He held academic positions at Cambridge and Oxford and presently holds an endowed Chair at McGill. Recognized as a Highly Cited Neuroscientist by the USA Institute for Scientific Information, he received numerous international recognitions, including honorary doctorates and the Order of Canada in 2010.

Sid O'Bryant

USA

Dr. Sid O'Bryant is the principal investigator of the Health & Aging Brain Study – Health Disparities (HABS-HD), which is the most comprehensive study of Alzheimer’s disease among the three largest racial/ethnic groups in the U.S. ever conducted – African Americans, Hispanics, non-Hispanic whites. The goal of the HABS-HD program is to understand the life course factors, including biological, sociocultural, environmental, and behavioral, that impact risk for Alzheimer’s disease in late life. This work will ultimately lead to population-specific precision medicine approaches to treating and preventing Alzheimer’s disease (i.e., “treating your Alzheimer’s disease”). In addition to being a global leader in health disparities in cognitive aging, Dr. O’Bryant is a global expert in the use of blood-based biomarkers for the generation of a precision medicine approach to novel diagnostic and therapeutic strategies for Alzheimer’s disease, Parkinson’s disease, Dementia with Lewy Bodies and Alzheimer’s disease among adults with Down Syndrome.

Tamas Fulop

Canada

Prof Tamas Fulop M.D, PhD, FRCPC is an internist-geriatrician and senior researcher at the Research Center at the Université de Sherbrooke. He completed his medical studies at the faculty of medicine of the University of Geneva. He made his PhD at Hungary. He was a postdoctoral fellow at Paris XII. He moved to the Université de Sherbrooke in 1993. His main research field is immunology in aging and age-related diseases, especially neurodegenerative diseases. He authored more than 400 papers. He led the memory clinic for more than 10 years. He is Editor-in-Chief of Gerontology. He is a fellow of the Canadian Academy of Health Sciences, Fellow of the Gerontological Society of America and corresponding member of the French Medical Academy.

Gene L. Bowman

USA

Gene L. Bowman, ND, MPH, is an Assistant Professor of Neurology at Harvard Medical School and Director of the Clinical Trials Unit and Brain Nutrition Laboratory at the McCance Center for Brain Health, Massachusetts General Hospital. Trained as a naturopathic physician, clinical investigator, and neuroepidemiologist, he has over 20 years of experience at the interface of nutrition, cognitive aging, and brain health, spanning work at Oregon Health C Science University, Nestlé Research, and now Harvard–Mass General Brigham.

Dr. Bowman leads NIH-funded clinical trials and cohort studies that use nutrient biomarkers, advanced neuroimaging, and blood–brain barrier measures to understand and modify risk for cognitive decline and dementia across the aging continuum. He has served as Global Head of Nutrition and Brain Health at the Nestlé Institute of Health Sciences, co-founded and chaired the Alzheimer’s Association ISTAART Nutrition, Metabolism and Dementia professional interest area, and sits on multiple national and international trial design and grant review committees.

At the 8th World Aging and Rejuvenation Conference (ARC-2026), Dr. Bowman brings a precision brain-nutrition perspective on how multi-omic nutrient biomarker profiling, omega-3 PUFA interventions, and multidomain lifestyle strategies can extend healthspan, support neurovascular resilience, and inform next-generation rejuvenation therapies for late-life brain health.